From library diversity to confirmed hits

Cyclic Peptide Screening
and Hit Validation Services

Discover target-binding macrocycles and confirm which hits merit further development.

CD ComputaBio connects library selection with independent peptide synthesis, binding confirmation and application-focused testing. Start with a target, an enriched hit list or a panel of designed candidates.

Target-focused selectionIndependent confirmationTraceable hit evidence
Schematic molecular illustration
Home / Peptide Drug Design & Development / Cyclic Peptide Screening & Hit Validation

Three ways to begin

Start with a Target, a Hit List or Designed Candidates

Cyclic peptide screening searches a chemically defined library for molecules associated with a target or assay response. Hit validation then asks whether individually prepared peptides reproduce that behavior and provide useful binding, selectivity or functional evidence.

Our peptide drug discovery support connects these stages around the next experimental decision. Screening campaigns and stand-alone validation projects can be scoped separately, so the work begins where your program needs evidence.

01 / TARGET TO HIT

Discover New Binders

Bring a target and intended application. Target readiness, library chemistry and counter-selection are reviewed before selection, sequence analysis and representative hit nomination.

02 / SCREENING FOLLOW-UP

Confirm Enriched Sequences

Provide a hit list from an internal or external screen. We review the original molecular format, independently prepare selected peptides and assess reproducibility in suitable assays.

03 / DESIGN TO EXPERIMENT

Test Designed Candidates

Move computational candidates into individual synthesis and testing. Candidates from AI-guided de novo cyclic peptide design can enter validation directly.

Your next step: share the target, existing sequences or design package. We will identify the appropriate entry stage and outline the material and assay requirements.

Define the biological question

Build the Screen Around the Target and Intended Use

A productive screen begins with an accessible, relevant target. We review construct boundaries, species, tags, purity, activity and available material, together with structural information and known ligands. For receptors and complexes, conformation, glycosylation and membrane context help determine whether a purified construct presents the desired surface.

Target immobilization and capture chemistry enter the experimental plan. Controls against affinity tags, beads and support surfaces help distinguish target recognition from background retention. Close homologs or designated counter-targets address a separate question: biological selectivity.

Cross-species binding, competitive inhibition and targeting applications require different selection pressures and confirmation assays. These objectives define the proposed controls, assay conditions and criteria for moving between stages.

Send target specifications for a screening plan →

Chemistry shapes discovery

Match Library Chemistry to the Discovery Question

Ring size, residue choices and closure chemistry determine which molecular features a screen can explore. Library selection balances target fit, translation compatibility and independent synthesis.

Project routeBest starting pointDesign and confirmation focus
mRNA display selectionA target requiring exploration of a broad encoded sequence space.Review randomized positions, encoded residues, cyclization chemistry, target presentation and selection controls.
Focused synthetic librariesA known motif, scaffold or initial structure–activity hypothesis.Prepare defined analogs and compare binding or functional responses using consistent material specifications.
Client-supplied candidate panelsExisting screening hits or computationally designed macrocycles.Reconcile complete chemical definitions, sample quality and the original evidence before testing individual compounds.

Ready-Made or Custom Libraries

Existing formats provide a practical starting point when their ring architecture fits the target. Custom projects can vary random-region length, residue composition or cyclization design. The brief distinguishes total peptide length from the variable region and theoretical sequence space from experimentally constructed diversity.

Noncanonical Amino Acids

Custom building blocks are assessed for translation, incorporation and reaction compatibility. Chemistry available during subsequent solid-phase synthesis may extend beyond the encoded library. Our peptide library design services help connect discovery objectives with a practical candidate space.

A staged discovery workflow

Identify Enriched Families with Relevant Controls

mRNA display links peptides to their encoding nucleic acids, allowing retained sequences to be recovered and amplified. Selection conditions and analytical checkpoints are adjusted around the target, background behavior and diversity of the emerging families.

01 / PREPARE

Qualify Target and Library

Review target handling, capture conditions, library format and control materials. Establish the readouts that will indicate useful recovery and acceptable background.

Decision: readiness for the first selection.

02 / SELECT

Capture Target-Associated Peptides

Apply the agreed selection and background-depletion conditions. Tune target concentration, washing or competition as evidence emerges rather than using stringency as a fixed recipe.

Decision: how to refine the next round.

03 / COMPARE

Review Enrichment and Controls

Analyze available round-by-round sequence data, relative abundance, family patterns and control recovery. Flag families enriched against capture reagents or designated counter-targets.

Decision: which families have useful support.

04 / NOMINATE

Choose Representative Hits

Select chemically feasible sequences across distinct families. Balance enrichment evidence with diversity so independent testing examines several binding hypotheses.

Decision: the synthesis and confirmation panel.

Sequence abundance and enrichment guide nomination; affinity is measured on individual peptides. Round count is agreed in the campaign plan and reviewed against enrichment, background and sequence convergence.

The critical transition

Confirm Hits as Independently Synthesized Cyclic Peptides

Schematic transition from a display-linked cyclic peptide to a free peptide and target binding confirmation
Schematic illustration of the transition from a display-linked candidate to an independent peptide for target-binding studies.

Preserve the Chemistry That Matters

Each hit is defined by sequence, residue stereochemistry, noncanonical building blocks, termini and cyclization connectivity. We compare the displayed construct with the intended free peptide, including linker remnants or terminal changes that may influence binding.

Selected hits and controls are synthesized and purified to the agreed specifications. HPLC and LC-MS establish chromatographic purity and mass consistency; complex connectivity, isomer or stereochemistry questions may require complementary characterization.

Linear, inactive, scrambled or site-mutated controls are chosen for the specific hypothesis. Sample handling records cover stock preparation, solvent, solubility and storage so biological comparisons can be interpreted against the material actually tested.

Evidence at the level your program needs

Build Evidence Across Binding, Selectivity and Function

Validation is organized around distinct questions. Direct binding establishes target recognition; competition and function test how that recognition relates to the intended biological effect. Each assay module has defined controls, concentration ranges and repeat measurements.

Validation layerExperimental questionTypical evidence
Binding confirmationDoes the independent peptide bind the target?Concentration-dependent measurements using suitable SPR, BLI or an alternative format; affinity analysis where supported.
Specificity assessmentDoes recognition persist after background and homolog comparisons?Tag and matrix controls, related-protein counterscreens and species comparisons within the agreed panel.
Competition studiesDoes the peptide affect the intended ligand interaction?Displacement or competition measurements supporting overlap or interference with a known interaction.
Functional confirmationDoes binding produce the desired response?Biochemical inhibition, receptor signaling or a relevant cellular endpoint, with IC50 or EC50 where appropriate.
Application-focused testingDoes the hit work in the proposed downstream format?Cell-surface recognition, internalization or retained binding after labeling or conjugation.
ASSAY QUALITY

Choose the Format Around the Molecule

Small-peptide signals, immobilization orientation, nonspecific retention and mass transport affect biophysical measurements. Reference surfaces, appropriate controls, replicate design and inspection of raw traces support meaningful interpretation. Kinetic parameters are reported when the experimental response and fit justify the model.

COMPLEMENTARY EVIDENCE

Resolve Format-Dependent Results

Confirmation can change the detection principle, labeling scheme or target presentation to investigate an apparent hit. SPR and BLI may share immobilization effects; an additional format should address the suspected source of bias. KD, IC50 and EC50 are reported with their assay conditions because they describe different measurements.

Already Have Synthesized Hits?

Share chemical structures, purity records, stock conditions and the original assay results. We can scope a confirmation panel around the evidence you already hold.

Plan Hit Confirmation ↗

Published discovery-to-validation example

Connect Sequence Selection with Independent Measurements

A published ADO study combined mRNA display with peptide synthesis, SPR and enzyme assays. The selected sequences showed different binding and inhibitory behavior after individual characterization, illustrating why enrichment, affinity and function are separate stages of evidence.1

The figure brings these stages together: library selection, nominated sequences, initial inhibition and detailed characterization of selected peptides. It provides a literature example for planning follow-up experiments; project-specific choices depend on the target and intended use.

Published ADO cyclic peptide study showing mRNA display selection, identified sequences, inhibition assays and SPR characterization
mRNA display selection followed by cyclic peptide synthesis, binding measurements and enzymatic characterization.1

Turn results into next steps

Select Hits for the Next Discovery Decision

Hit prioritization combines reproducibility, chemical quality, affinity, selectivity, function, solubility and family diversity. Acceptance criteria reflect the application: a research probe, receptor modulator and targeting ligand may require different evidence.

ADVANCE

Build on Confirmed Recognition

Independent binding and relevant biological results support focused analog design. Define the substitutions, ring changes or property studies that can improve the most informative families.

INVESTIGATE

Resolve an Evidence Gap

Format-dependent responses or disagreement between binding and function trigger targeted checks. Examine compound handling, controls, construct relevance and assay interference before expanding the series.

REVISIT

Refine the Discovery Strategy

When free peptides do not reproduce the expected signal, review library chemistry, target presentation and selection conditions. The report proposes a revised experiment or alternative starting point.

For confirmed families, cyclic peptide structure modeling can support substitution hypotheses, while peptide developability assessment helps prioritize property questions. Programs seeking oral exposure can continue into our oral cyclic peptide discovery services.

A traceable package for project review

Receive a Clear Hit Validation Package

Deliverables follow the agreed entry stage and experimental scope. Sample identifiers connect chemical definitions, analytical records, assay outputs and the final candidate ranking.

✓

Screening Strategy and Target Assessment

Target format, library choice, controls, counter-selection plan and stage criteria for the discovery campaign.

✓

Selection and Sequence Analysis

Agreed round data, sequence processing, enrichment trends, family assignments and nomination rationale.

✓

Chemically Defined Hit Panel

Sequences, stereochemistry, modifications, cyclization definitions, batch identifiers and analytical records.

✓

Binding and Selectivity Results

Assay conditions, raw traces or response data, controls, repeats and supported affinity or kinetic analyses.

✓

Functional and Application Data

Contracted competition, biochemical, cell-based or conjugation-related results with their experimental context.

✓

Hit Prioritization and Next Steps

An integrated ranking, remaining evidence gaps and recommendations for confirmation or focused optimization.

The proposal specifies candidate numbers, selection rounds, synthesis quantity and purity, assay panels and data files, including NGS files where applicable.

Select the assay for the application

Build a Useful Starting Point for Your Program

RECEPTOR & EXTRACELLULAR LIGANDS

Confirm Relevant Recognition

Combine purified-target binding with cell-surface or competition studies when the native environment affects accessibility. Define whether the goal is simple recognition or receptor modulation.

PPI & ENZYME MODULATORS

Link Binding to Activity

Follow direct binding with interaction disruption or enzyme assays. For intracellular programs, cellular activity and target-engagement studies address exposure and biological relevance.

CONJUGATES & RADIOLIGANDS

Evaluate Attachment Tolerance

Prioritize ligands with a practical conjugation position. Compare the parent peptide with the intended labeled or conjugated format, then assess uptake or retention as required.

RESEARCH PROBES

Establish Interpretable Controls

Confirm recognition before introducing fluorophores or affinity handles. Matched inactive controls and labeled-versus-unlabeled comparisons help support mechanistic interpretation.

Project questions

Frequently Asked Questions

Can you screen against a target supplied by our team?

Yes. Share the construct, tags, buffer, quantity and available activity data. These details support a target-readiness review and selection strategy.

Can you validate hits from another provider?

Yes. Provide complete molecular definitions, the original display or assay format and supporting results. Validation can begin with resynthesis or qualified existing samples.

Can AI-designed peptides enter testing directly?

Yes. Chemically defined candidates can proceed to individual synthesis, quality assessment and binding or functional testing. The testing plan follows the design hypothesis.

Can the library include custom noncanonical amino acids?

Custom residues and ring chemistries are reviewed for incorporation, cyclization and synthesis compatibility. Share chemical structures so feasibility and any preliminary work can be assessed.

How are rounds and hit criteria defined?

The proposal sets an initial campaign scope and review points. Criteria incorporate enrichment, background, chemical quality and independent assays in relation to the intended application.

What if enrichment does not produce confirmed binding?

We review peptide identity, handling, target state and screening-format effects, then recommend focused confirmation or a revised selection strategy based on the observed evidence.

Make your next discovery decision

Define Your Screening
and Validation Plan.

Share your target, available materials, screening history and intended application. We will help define the library strategy, confirmation assays and evidence needed to move your program forward.

For sequences, structures or supporting records, email contact@computabio.com.

Reference

  1. Jiramongkol, Y.; Patel, K.; Johansen-Leete, J.; et al. An mRNA-display derived cyclic peptide scaffold reveals the substrate binding interactions of an N-terminal cysteine oxidase. Nature Communications 2025, 16, 4761. doi:10.1038/s41467-025-59960-3. Figure 1 reproduced under Creative Commons Attribution 4.0.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.

x
Need help getting the data you need?

Talk to our technical team about your project!

I Want To Talk